Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ofatumumab in Relapsing Multiple Sclerosis (APOLITOS)
NCT03249714Phase 2Completed
- Sponsor
- Novartis
- Start
- Mar 2018
- Primary completion
- Dec 2019
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial of ofatumumab in multiple sclerosis (MS) (2 arms), sponsored by Novartis. Primary endpoint: Number of Gadolinium-enhancing T1 Lesions Per MRI Scan at Week 24. Started Mar 2018; status: completed.
02
Drugs
ofatumumab
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT03249714.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03249714.